唐人神(002567.SZ):擬投1.3億元建設動物營養生物飼料研產銷基地項目
格隆匯12月14日丨唐人神(002567.SZ)公佈,公司於2021年12月14日召開第八屆董事會第四十四次會議,審議通過了《關於簽署<投資協議書>的議案》,同意公司與仁化縣人民政府簽署《投資協議書》,公司以自有資金投資建設動物營養生物飼料研產銷基地項目。項目計劃總投資1.3億元人民幣。
主要建設內容:建設年產30萬噸動物營養生物飼料生產線、綜合辦公大樓、研發中心等具備研產銷一體化能力的生產、生活設施。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.